article thumbnail

Two Founders of Piracy Giant Zone-Telechargement Sentenced in France

TorrentFreak

For those who care to remember it, November 2016 was a dark month for communities with a penchant for sharing files. Then in November 2016, as French authorities swooped, What.cd The goal was to identify financial accounts, assets, advertising agencies, and the site’s hosting servers.

article thumbnail

2021 IP Year in Review

IPilogue

of the Patent Act on June 24, 2016. Continued Debates over AI as an Inventor. Around the world, patent registrars grappled with patent applications that credit artificial intelligence software as the inventor. This article summarizes the top developments reported on our blog and in patents, trademarks, and copyright law in 2021.

IP 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

Above the Fold

In order in ensure the best protection, trade dress should be considered in circumstances where a fashion product has sufficiently established that the design has secondary meaning, the design’s use has been continuous, and the inventor is willing to continuously police the marketplace and enforce their right. 102(a)(5); see also Darden v.

article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

LexBlog IP

In order in ensure the best protection, trade dress should be considered in circumstances where a fashion product has sufficiently established that the design has secondary meaning, the design’s use has been continuous, and the inventor is willing to continuously police the marketplace and enforce their right. Peters , 488 F.3d

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

2016; resubmitted May 2018). September 23, 2016. August 30, 2016. April 5, 2016. November 2016. Citing this joint statement in a July 2021 press release , FDA announced that it had issued an untitled letter to Amgen citing issues with a banner advertisement of its biological product, Neulasta ® (pegfilgrastim).